Skip to main content

Astellas Pharma Unsp/Adr(ALPMY)
OTC US

Today's Change
Delayed Last Update
Day Low14.8700
Day High15.1800
Open:15.1682
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Astellas Pharma Unsp/Adr

Select a category then submit the form to load news
Tipranks
Nomura downgrades Astellas Pharma (ALPMF) to a Hold
Tipranks
SMBC Nikko Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
Tipranks
Astellas Pharma (ALPMF) Gets a Hold from Morgan Stanley
Tipranks
Goldman Sachs Remains a Buy on Astellas Pharma (ALPMF)
Tipranks
Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)
Tipranks
Daiwa Sticks to Their Sell Rating for Astellas Pharma (ALPMF)
Tipranks
UBS Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
Tipranks
Macquarie Sticks to Their Buy Rating for Astellas Pharma (ALPMF)
Tipranks
Citi Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
Tipranks
Astellas Pharma (ALPMF) Gets a Buy from Goldman Sachs
Tipranks
Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)
Tipranks
Pfizer and Astellas Pharma’s Promising Prostate Cancer Study: A Potential Game-Changer?
Tipranks
Pfizer and Astellas Pharma’s Prostate Cancer Study: A Potential Game-Changer?
Tipranks
Astellas Pharma’s ASP3082 Study: A New Hope for KRAS G12D Mutation in Cancer
Tipranks
Astellas Pharma’s Phase 3 Study on Fezolinetant: A Potential Game-Changer for Menopausal Hot Flashes
Tipranks
Astellas Pharma’s Fezolinetant Study: A Potential Game-Changer for Menopause Treatment
Tipranks
Astellas Pharma Advances AMD Treatment with New ASP3021 Study
Tipranks
Astellas Pharma’s Promising AML Study: A Potential Game Changer?
Tipranks
Pfizer and Astellas Advance Prostate Cancer Study with Promising Drug Combo
Tipranks
Pfizer and Astellas Pharma’s Promising mCRPC Study Update
Tipranks
Astellas Pharma’s New Study on ASP3021: A Potential Game-Changer for AMD Treatment
Tipranks
Astellas Pharma Completes Key Study on Roxadustat for Renal Anemia
Tipranks
Astellas Pharma’s Fezolinetant Study: A Potential Game-Changer for Menopause Treatment
Tipranks
Astellas Pharma’s ASP3082 Study: A New Hope for Advanced Solid Tumors
Tipranks
Astellas Pharma’s ASP0367 Study Terminated: Implications for Investors
Tipranks
Astellas Pharma’s ASP3021 Study: A Promising Step in AMD Treatment
Tipranks
Astellas Pharma’s Fezolinetant Study: A Potential Game-Changer for Menopausal Treatment
Tipranks
Astellas Pharma’s ASP3082 Study: A Potential Game-Changer in Oncology
Tipranks
Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
Motley Fool
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Motley Fool
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years
MarketBeat
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Profile

Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.